In comparison to developing generics for small molecule drugs, the development of a biosimilar is far more complex, time consuming and expensive.
Biosimilars are not required to complete the same number of clinical trials as the reference product, however they are subject to more rigorous analytical and clinical development requirements than small molecule generics.
Unlike small molecule generics, biologics have inherent product variations that result from the manufacturing process and complexity of the molecules. Slight differences exist across different manufactured batches of all biologic products, and as a result, biosimilars are defined as being “highly similar and demonstrate no clinically meaningful differences to the products they reference”.
We employ a proprietary standardised process to ensure the right reference sequence is used from the outset of biosimilar development. This includes peptide mass fingerprinting, sequence database and patent searches, intact mass analysis, and X-ray crystallography technology.
Our Biosimilarity by Design™ approach, based on QbD principles, tests and confirms biosimilarity at every stage of development, using world-leading internal and independent external analytics capabilities.
Our clinical approach is designed to meet all global standards for biosimilar approval, including the US FDA, EU EMA and TGA.
We develop and screen a multitude of clones through our proprietary high through-put screening (HTS) technology. This ensures only the best producing clones, expressing the right biosimilar, are used.
We conduct clinical trials in collaboration with world-leading CROs and take consultation from regulatory bodies, to allow for the most streamlined pathway towards global biosimilar approval.
Our partner, Serum Institute of India, is the largest manufacturer of biologics in the world. Serum Institute’s legacy and experience of low cost, high quality manufacture, at very large scale will be leveraged to provide the most competitive pricing to NeuClone’s biosimilars.
NeuClone’s internally developed and patented NeuMAX® platform carries major manufacturing advantages from the outset, including superior cell viability, low cost medium formulation and enhanced growth characteristics.